Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DaVita investigated by Justice

This article was originally published in The Gray Sheet

Executive Summary

Dialysis services firm will provide documents relating to medical director compensation, joint venture agreements with physicians and drug services to DoJ under a March 4 subpoena. The U.S. Attorney for the Eastern District of Missouri's investigation "significantly overlaps" with a similar action begun in February 2001 by the U.S. attorney in Philadelphia, the firm notes. DaVita acquisition target Gambro settled similar issues with the St. Louis attorney's office in December 2004 (1"The Gray Sheet" Dec. 13, 2004, p. 12)...

You may also be interested in...



Gambro Sale Of U.S. Dialysis Services Leaves $2 Bil. For Possible Acquisitions

Gambro's plan to refocus on its core renal and blood bank product offerings by divesting its U.S. dialysis services business provides about $2 bil. for potential acquisitions in related fields

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel